Thursday, 12 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 4, 2026

Goldman Sachs has blunt message on gold price for rest of 2026

View original at finance.yahoo.com
Goldman Sachs has blunt message on gold price for rest of 2026 Gold just had its worst month in over a decade. Goldman Sachs is not budging…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The March sell-off does not change the structural case for gold, and the buyers who drove gold higher are still there

    60% confidence
  • The March sell-off does not change the structural case for gold and the buyers who drove gold higher are still there

    60% confidence
  • Emerging-market central banks will purchase about 60 tonnes of gold per month in 2026

    60% confidence
  • Emerging-market central banks will purchase about 60 tonnes of gold per month in 2026 as countries diversify reserves away from the U.S. dollar

    60% confidence
  • Private investors who bought gold as a hedge against long-term macro risks are not selling and these positions are stickier than event-driven bets

    60% confidence
  • Risks to the upgraded forecast are significantly skewed to the upside because private-sector investors may diversify further on lingering global policy uncertainty

    60% confidence
  • Concerns over long-term government debt levels and monetary policy credibility are driving physical bar purchases by high-net-worth individuals and call option buying by institutions

    60% confidence
  • China's central bank extended its gold purchases for 15 consecutive months through January 2026

    60% confidence
  • Total EM central bank gold purchases will reach approximately 850 tonnes in 2026

    60% confidence
  • Private investors who bought gold as a hedge against long-term macro risks are not selling, and these positions are stickier than event-driven bets

    60% confidence
  • Risks to the upgraded forecast are significantly skewed to the upside because private-sector investors may diversify further on lingering global policy uncertainty

    60% confidence
  • Goldman expects a further half-point of Fed easing in 2026, which it estimates adds roughly $120 per ounce to gold's price support

    60% confidence
  • Goldman Sachs reaffirmed its $5,400 per ounce year-end target for gold despite March 2026 sell-off

    60% confidence
  • Total emerging market central bank gold purchases will reach approximately 850 tonnes in 2026

    60% confidence
  • Goldman Sachs maintains $5,400 per ounce year-end target for gold despite March 2026 sell-off

    60% confidence
  • Western gold ETFs added roughly 500 tonnes since the start of 2025, running well ahead of what Federal Reserve rate cuts alone would explain

    60% confidence
  • Federal Reserve will implement a further half-point of easing in 2026, which adds roughly $120 per ounce to gold's price support

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com